# Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

> **NCT01827943** · PHASE2 · COMPLETED · sponsor: **Institut Bergonié** · enrollment: 54 (actual)

## Conditions studied

- Relapsed Bladder Cancer

## Interventions

- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01827943
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2014-12
- **Final completion:** 2016-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827943, "Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01827943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*